Abstract
Several myelin-associated proteins in the central nervous system (CNS) have been identified as inhibitors of axonal regeneration following the injury of the adult vertebrate CNS. Among these inhibitors, myelin-associated glycoprotein (MAG), Nogo, and oligodendrocyte- myelin glycoprotein (OMgp) are well characterized. Recently, the repulsive guidance molecule (RGM) was included as a potent myelin-derived neurite outgrowth inhibitor in vitro and in vivo. The discovery of the receptors and downstream signals of these inhibitors enabled further understanding of the mechanism underlying the failure of axonal regeneration. The activation of RhoA and its effector Rho kinases (ROCK) after the ligation of these inhibitors to the corresponding receptors has been shown to be a key element for axonal growth inhibition. Blockade of the Rho-ROCK pathway reverses the inhibitory effects of these inhibitors in vitro and promotes axonal regeneration in vivo. Therefore, the Rho-ROCK inhibitors have a therapeutic potential against injuries to the human CNS, such as spinal cord injuries.
Keywords: Myelin, p75, Rho, repulsive guidance molecule, regeneration, central nervous system
Current Pharmaceutical Design
Title: Rho-ROCK Inhibitors as Emerging Strategies to Promote Nerve Regeneration
Volume: 13 Issue: 24
Author(s): Takekazu Kubo, Katsuhiko Hata, Atsushi Yamaguchi and Toshihide Yamashita
Affiliation:
Keywords: Myelin, p75, Rho, repulsive guidance molecule, regeneration, central nervous system
Abstract: Several myelin-associated proteins in the central nervous system (CNS) have been identified as inhibitors of axonal regeneration following the injury of the adult vertebrate CNS. Among these inhibitors, myelin-associated glycoprotein (MAG), Nogo, and oligodendrocyte- myelin glycoprotein (OMgp) are well characterized. Recently, the repulsive guidance molecule (RGM) was included as a potent myelin-derived neurite outgrowth inhibitor in vitro and in vivo. The discovery of the receptors and downstream signals of these inhibitors enabled further understanding of the mechanism underlying the failure of axonal regeneration. The activation of RhoA and its effector Rho kinases (ROCK) after the ligation of these inhibitors to the corresponding receptors has been shown to be a key element for axonal growth inhibition. Blockade of the Rho-ROCK pathway reverses the inhibitory effects of these inhibitors in vitro and promotes axonal regeneration in vivo. Therefore, the Rho-ROCK inhibitors have a therapeutic potential against injuries to the human CNS, such as spinal cord injuries.
Export Options
About this article
Cite this article as:
Takekazu Kubo , Katsuhiko Hata , Atsushi Yamaguchi and Toshihide Yamashita , Rho-ROCK Inhibitors as Emerging Strategies to Promote Nerve Regeneration, Current Pharmaceutical Design 2007; 13 (24) . https://dx.doi.org/10.2174/138161207781368657
DOI https://dx.doi.org/10.2174/138161207781368657 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Inhibition of Rho/Rho-Kinase as Therapeutic Strategy to Promote CNS Axonal Regeneration
Central Nervous System Agents in Medicinal Chemistry SOD1 Aggregation and ALS: Role of Metallation States and Disulfide Status
Current Topics in Medicinal Chemistry Mitochondrial VDAC1: Function in Cell Life and Death and a Target for Cancer Therapy
Current Medicinal Chemistry Overactive Bladder Syndrome, Detrusor Overactivity and the Botulinum Toxin
Reviews on Recent Clinical Trials An Update on Peptide Drugs for Voltage-Gated Calcium Channels
Recent Patents on CNS Drug Discovery (Discontinued) Minocycline: Neuroprotective Mechanisms in Parkinsons Disease
Current Pharmaceutical Design Sulforaphane Treatment of Young Men with Autism Spectrum Disorder
CNS & Neurological Disorders - Drug Targets Preclinical Studies and Clinical Trials with Mesenchymal Stem Cell for Demyelinating Diseases: A Systematic Review
Current Stem Cell Research & Therapy Thoracic Aortic Aneurysm: Blood Pressure and Inflammation as Key Factors in the Development of Aneurysm Dissection
Current Pharmaceutical Design Palmitoylethanolamide Restores Myelinated-Fibre Function in Patients with Chemotherapy-Induced Painful Neuropathy
CNS & Neurological Disorders - Drug Targets Glycine/NMDA Receptor Antagonists as Potential CNS Therapeutic Agents: ACEA-1021 and Related Compounds
Current Topics in Medicinal Chemistry Natural Occurring Compounds Inhibit Osteoclastogenesis via Targeting NFATc1-related Signaling Pathways
Current Drug Targets The Use of Growth Factors and Mesenchymal Stem Cells in Orthopaedics: In particular, their use in Fractures and Non-Unions: A Systematic Review
Current Stem Cell Research & Therapy NK-1 Receptor Antagonists: A New Generation of Anticancer Drugs
Mini-Reviews in Medicinal Chemistry Gene Therapy for Ocular Neovascularization
Current Gene Therapy Editorial [ Medicines Da Vinci Code: Deciphering the Intricate Origins of Clinical Neurovascular Pathology K. Maiese ]
Current Neurovascular Research Noradrenergic System in Down Syndrome and Alzheimer’s Disease A Target for Therapy
Current Alzheimer Research Relevance of Dopamine D2/Neurotensin NTS1 and NMDA/Neurotensin NTS1 Receptor Interaction in Psychiatric and Neurodegenerative Disorders
Current Medicinal Chemistry Central Nervous System-Related
Current Bioactive Compounds Nanoparticles, Neurotoxicity and Neurodegenerative Diseases
Current Drug Metabolism